
    
The genomic variant c.5615G>A, resulting in the amino acid substitution p.Arg1872Gln in the SCN8A gene, has been identified as a de novo mutation, meaning it was not present in either parent of the affected individuals [1]. This variant is associated with early-onset seizures, developmental delay, and cognitive impairment, as demonstrated in clinical exome sequencing studies of patients with these phenotypes [1]. The SCN8A gene encodes the voltage-gated sodium channel Nav1.6, which is critical for the initiation and propagation of action potentials in neurons, and mutations in this gene can lead to a spectrum of epilepsy phenotypes [6].Functional studies of the p.Arg1872Gln variant have shown that it, along with other mutations at the same arginine residue (p.Arg1872Trp and p.Arg1872Leu), affects the electrophysiological properties of the Nav1.6 channel when expressed in ND7/23 cells. These mutations have been characterized by their interactions with other proteins such as FGF14, G-protein subunit Gbetagamma, and sodium channel subunit beta1, which are assessed by coimmunoprecipitation [1]. The p.Arg1872Gln variant is one of several recurrent mutations at the arginine 1872 residue, which is evolutionarily conserved and located in a region with a high occurrence of CpG dinucleotides, making it a hotspot for de novo mutations due to cytosine methylation and deamination [2].The clinical significance of the p.Arg1872Gln variant is further supported by its classification in ClinVar, where it has been submitted a total of five times with a pathogenic designation. This variant has been observed in multiple unrelated individuals, indicating a recurring mutation event [2]. Moreover, systematic comparisons of the p.Arg1872Gln variant with other SCN8A epilepsy mutations have revealed common dysfunctions in resurgent current, which is a key factor in neuronal excitability and may explain the seizure activities observed in patients [4].In summary, the c.5615G>A p.Arg1872Gln variant in the SCN8A gene is a pathogenic missense mutation associated with a range of neurological symptoms, including early-onset seizures and developmental delays. Its pathogenicity is supported by both functional studies and clinical observations, as well as its recurrent nature and presence in a mutation hotspot within the gene [1][2][4].

SCN8A遺伝子におけるアミノ酸置換p.Arg1872Glnを引き起こすゲノム変異c.5615G>Aは、de novo変異として同定されました。これは、影響を受けた個人の両親のいずれにもこの変異が存在しなかったことを意味します[1]。この変異は、早期発症のてんかん発作、発達遅延、認知障害と関連しており、これらの表現型を持つ患者の臨床エクソーム解析研究で示されています[1]。SCN8A遺伝子は電位依存性ナトリウムチャネルNav1.6をコードしており、このチャネルはニューロンにおける活動電位の開始と伝播に重要な役割を果たします。この遺伝子の変異は、てんかんの多様な表現型を引き起こす可能性があります[6]。

p.Arg1872Gln変異の機能研究では、同じアルギニン残基における他の変異（p.Arg1872Trpおよびp.Arg1872Leu）とともに、ND7/23細胞で発現させた際にNav1.6チャネルの電気生理学的特性に影響を与えることが示されています。これらの変異は、FGF14、Gタンパク質サブユニットGbetagamma、ナトリウムチャネルサブユニットbeta1などの他のタンパク質との相互作用によって特徴付けられており、これらの相互作用は共免疫沈降法によって評価されています[1]。p.Arg1872Gln変異は、進化的に保存されているアルギニン1872残基における複数の再発性変異の1つであり、この領域はCpG二塩基配列の高頻度発生を特徴とし、シトシンのメチル化と脱アミノ化によるde novo変異のホットスポットとなっています[2]。

p.Arg1872Gln変異の臨床的意義はClinVarでの分類によってさらに支持されており、病原性指定で合計5回提出されています。この変異は複数の無関係な個人で観察されており、再発性変異イベントを示しています[2]。さらに、p.Arg1872Gln変異と他のSCN8Aてんかん変異との体系的な比較により、ニューロンの興奮性において重要な要素であるリサージェント電流の共通の機能障害が明らかになり、患者に見られる発作活動を説明する可能性があります[4]。

まとめると、SCN8A遺伝子におけるc.5615G>A p.Arg1872Gln変異は、早期発症のてんかん発作や発達遅延を含む一連の神経症状と関連する病原性ミスセンス変異です。その病原性は、機能研究と臨床観察、さらに遺伝子内の変異ホットスポットにおける再発性の性質によって支持されています[1][2][4]。
    
## References
- [1] Wagnon JL et al. (2016). "Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy." Annals of clinical and translational neurology, 3(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/26900580/)
- [2] Wagnon JL et al. (2015). "Recurrent and Non-Recurrent Mutations of SCN8A in Epileptic Encephalopathy." Frontiers in neurology, 6() [PubMed](https://pubmed.ncbi.nlm.nih.gov/26029160/)
- [3] Komatsu K et al. (2024). "Identifying pathogenic variants in rare pediatric neurological diseases using exome sequencing." Scientific reports, 14(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/39433808/)
- [4] Pan Y et al. (2020). "Distinct functional alterations in SCN8A epilepsy mutant channels." The Journal of physiology, 598(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/31715021/)
- [5] Arafat A et al. (2017). "Unexplained Early Infantile Epileptic Encephalopathy in Han Chinese Children: Next-Generation Sequencing and Phenotype Enriching." Scientific reports, 7() [PubMed](https://pubmed.ncbi.nlm.nih.gov/28387369/)
- [6] Johannesen KM et al. (2019). "The spectrum of intermediate SCN8A-related epilepsy." Epilepsia, 60(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30968951/)
- [7] Hammer MF et al. (2017). "Neurotransmitters and Sodium Channelopathies; Possible Link?" Pediatric neurology briefs, 31(3) [PubMed](https://pubmed.ncbi.nlm.nih.gov/29184379/)
- [8] Wong JC et al. (2024). "Carvedilol increases seizure resistance in a mouse model of SCN8A-derived epilepsy." Frontiers in pharmacology, 15() [PubMed](https://pubmed.ncbi.nlm.nih.gov/38895634/)
- [9] Horvath GA et al. (2016). "Secondary neurotransmitter deficiencies in epilepsy caused by voltage-gated sodium channelopathies: A potential treatment target?" Molecular genetics and metabolism, 117(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/26647175/)
- [10] Atkin TA et al. (2018). "A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy." Epilepsia, 59(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/29574705/)
- [11] Tidball AM et al. (2020). "Variant-specific changes in persistent or resurgent sodium current in SCN8A-related epilepsy patient-derived neurons." Brain : a journal of neurology, 143(10) [PubMed](https://pubmed.ncbi.nlm.nih.gov/32968789/)
- [12] Zhang X et al. (2024). "[Clinical features and genetic analysis of five children with epilepsies due to variants of SCN8A gene]." Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics, 41(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38311555/)
- [13] Maya Atanasoska et al. (2018). "SCN8A p.Arg1872Gln mutation in early infantile epileptic encephalopathy type 13: Review and case report" Biotechnology & Biotechnological Equipment, 32 [PubMed](https://doi.org/10.1080/13102818.2018.1532815)
- [14] Garcia-Uzquiano R et al. (2024). "Genetic testing, another important tool in presurgical evaluation of focal epilepsies in childhood." Epilepsia open, 9(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38829689/)
- [15] Hack JB et al. (2024). "Machine learning models reveal distinct disease subgroups and improve diagnostic and prognostic accuracy for individuals with pathogenic SCN8A gain-of-function variants." Biology open, 13(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38466077/)

    
## ClinVar Submissions
- **[RCV000239745](https://www.ncbi.nlm.nih.gov/clinvar/RCV000239745/)**: Developmental and epileptic encephalopathy, 13
- **[RCV000189290](https://www.ncbi.nlm.nih.gov/clinvar/RCV000189290/)**: not provided
- **[RCV000523884](https://www.ncbi.nlm.nih.gov/clinvar/RCV000523884/)**: not provided
- **[RCV000704631](https://www.ncbi.nlm.nih.gov/clinvar/RCV000704631/)**: Early infantile epileptic encephalopathy with suppression bursts
- **[RCV002517898](https://www.ncbi.nlm.nih.gov/clinvar/RCV002517898/)**: Early infantile epileptic encephalopathy with suppression bursts

    